Explore more publications!

Nepal Healthcare Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.

Press releases published on October 30, 2025

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
Bright Minds Biosciences to Present at Upcoming Conferences
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025
Nyxoah Publiera ses Résultats Financiers du Troisième Trimestre 2025 le 13 Novembre 2025
Corbus Pharmaceuticals Announces Proposed Public Offering
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Primary Care Physician Use of Counterpart Assistant (CA) Technology Associated With Earlier Diagnosis And Less Frequent Hospitalization In Underserved Populations
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025
Synergy CHC Corp. Announces Third Quarter 2025 Earnings and Conference Call Information
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
LogicMark, Inc. to Announce Third Quarter 2025 Financial Results on November 12, 2025
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
Stryker reports third quarter 2025 operating results
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development
Galapagos kondigt wijzigingen aan in de Raad van Bestuur om de strategische focus op business development te versnellen
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions